ZNTL

1.3600.00%
JB

James B. Bucher

Chief Legal Officer & Corporate Secretary

Mr. James B. Bucher, also known as Jim, J.D, serves as Chief Legal Officer and Company Secretary at Zentalis Pharmaceuticals, Inc. since September 18, 2025. Previously, he served as the Chief Legal Officer of Harpoon Therapeutics, Inc. from December 2023 until its acquisition by Merck (NYSE: MRK) in March 2024. He served as an Executive Vice President, General Counsel at Eliem Therapeutics, Inc. since October 2020 until February 10, 2023 and also served as its Secretary. He served as an Executive Vice President of Alder Biopharmaceuticals Inc. from 2016 to 2019 and served as its General Counsel since January 2016 until 2019. Mr. Bucher served as Corporate Secretary at Alder Biopharmaceuticals Inc. until October 22, 2019. Mr. Bucher served as Senior Vice President at Alder Biopharmaceuticals Inc. since January 2016. Mr. Bucher served as Vice President of Corporate Legal Affairs at Exelixis Inc. from July 2007 to November 2014. During 2015, Mr. Bucher served as a consultant providing legal services to several life sciences companies. He served as Secretary and Corporate Compliance Officer of Exelixis Inc. since July 2007 until 2014. He is a veteran legal professional with legal experience, providing counsel on a wide range of strategic and business issues, general corporate matters, compliance, corporate governance, corporate finance transactions, federal securities laws, merger and acquisitions and commercial matters. From 1991 to 2007, Mr. Bucher practiced as a corporate attorney at the international law firm Shearman & Sterling LLP, becoming a Partner in 2001. Mr. Bucher holds a J.D. with distinction from Emory University School of Law and a B.A. in Biology from Colgate University.

Positions